Evotec (EVT) Panoramica del titolo
Evotec SE opera come partner per la scoperta e lo sviluppo di farmaci per l'industria farmaceutica e biotecnologica in tutto il mondo. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 2/6 |
| Crescita futura | 3/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 4/6 |
| Dividendi | 0/6 |
EVT Community Fair Values
Create NarrativeSee what 46 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Evotec SE
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | €3.45 |
| Massimo di 52 settimane | €7.30 |
| Minimo di 52 settimane | €3.18 |
| Beta | 1.26 |
| Variazione di 1 mese | -1.71% |
| Variazione a 3 mesi | -25.38% |
| Variazione di 1 anno | -45.78% |
| Variazione a 3 anni | -83.02% |
| Variazione a 5 anni | -91.98% |
| Variazione dall'IPO | -78.12% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Aug 04
EVT: INDiGO Platform And 2026 Guidance Will Drive Future Upside
Analysts have adjusted their price target on Evotec to €4.90 from €6.83, reflecting updated assumptions on fair value, discount rate, revenue, profit margin and future P/E expectations. What’s in the News for Evotec Niagen Bioscience selected Evotec as the contract research organization to support advancement of its oral small molecule NB4168 for Ataxia Telangiectasia, with Evotec providing pharmacokinetic and pharmacodynamic studies plus bioanalytical method validation in collaboration with NAD Pharmaceuticals.
Aggiornamento narrativa • Jul 21
EVT: Guidance Reset And Manufacturing Rollout Will Likely Constrain Future Re rating
Analysts have lowered their price target on Evotec, citing a shift to a more conservative fair value estimate, along with changes in the discount rate, revenue growth assumptions, profit margin expectations and future P/E, which together point to a reduced implied equity value in € terms. What’s in the News for Evotec Evotec reported preliminary unaudited H1 2026 figures, with Group revenues of about €300.1 million and an adjusted Group EBITDA loss of about €42.7 million, highlighting solid cash resources of about €465.6 million as of June 30, 2026.Recent updates
Aggiornamento narrativa • Aug 04
EVT: INDiGO Platform And 2026 Guidance Will Drive Future Upside
Analysts have adjusted their price target on Evotec to €4.90 from €6.83, reflecting updated assumptions on fair value, discount rate, revenue, profit margin and future P/E expectations. What’s in the News for Evotec Niagen Bioscience selected Evotec as the contract research organization to support advancement of its oral small molecule NB4168 for Ataxia Telangiectasia, with Evotec providing pharmacokinetic and pharmacodynamic studies plus bioanalytical method validation in collaboration with NAD Pharmaceuticals.Aggiornamento narrativa • Jul 21
EVT: Guidance Reset And Manufacturing Rollout Will Likely Constrain Future Re rating
Analysts have lowered their price target on Evotec, citing a shift to a more conservative fair value estimate, along with changes in the discount rate, revenue growth assumptions, profit margin expectations and future P/E, which together point to a reduced implied equity value in € terms. What’s in the News for Evotec Evotec reported preliminary unaudited H1 2026 figures, with Group revenues of about €300.1 million and an adjusted Group EBITDA loss of about €42.7 million, highlighting solid cash resources of about €465.6 million as of June 30, 2026.Aggiornamento narrativa • Jul 07
EVT: Rich P/E Will Likely Outweigh Benefits Of New Manufacturing Initiative
Analysts have raised their fair value estimate for Evotec from €4.0 to €4.5. They attribute this change to slightly adjusted discount rate assumptions, modestly higher expectations for revenue growth and profit margins, and a higher future P/E multiple in their updated models. What’s in the News for Evotec Evotec, through its Just – Evotec Biologics unit, launched J.TRAIN, a turnkey offering that lets biopharmaceutical companies deploy its proprietary continuous biologics manufacturing technology directly inside their own facilities, combining modular cleanrooms, industry-standard equipment and cGMP-compliant process automation.Aggiornamento narrativa • Jun 23
EVT: Rich P/E Expectations Will Likely Outweigh Alliance And Governance Progress
Analysts have revised their fair value estimate for Evotec to €4.0 from €4.4, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations. What’s in the News for Evotec Evotec and Almirall nominated a small molecule preclinical development candidate in medical dermatology from their multi target drug discovery alliance, focused on immune mediated inflammatory skin diseases with high unmet medical need.
Aggiornamento narrativa • Jun 06
EVT: AI And Royalty Pipeline Will Support Future Earnings Upside
Analysts have slightly adjusted their outlook on Evotec, keeping the fair value estimate steady at €10.00 while fine tuning assumptions around discount rate, revenue growth, profit margin, and future P/E to reflect updated expectations for the business. What's in the News Evotec appointed Rui Wang as Executive Vice President, Head of Global In Silico and AI, to lead the integration of computational science and data driven decision making across its R&D operations, positioning AI and in silico capabilities as key parts of the company’s commercial offering.Aggiornamento narrativa • May 23
EVT: Future Milestone And Royalty Stream Will Support Earnings Upside
Analysts have trimmed their price target on Evotec from €10.40 to €10.00, citing updated assumptions for revenue growth, profit margins, discount rate and future P/E that now sit slightly below prior estimates but remain within a similar range. What's in the News Evotec and Almirall nominated a small molecule preclinical development candidate for immune mediated inflammatory skin diseases, using Evotec’s AI/ML supported discovery and preclinical platforms, with potential success based milestones of up to €230 million per program plus high single digit royalties on net sales (Key Developments).Aggiornamento narrativa • May 04
EVT: Activist Proposals And 2026 Guidance Will Drive Future Upside
Analysts have slightly reduced their price target on Evotec to €6.83 from €6.92, reflecting updated views on discount rates, revenue growth, profit margins and future P/E assumptions. What's in the News Evotec expects full year 2026 group revenues of approximately €700 million to €780 million, with constant currency guidance of €730 million to €810 million (company guidance).Aggiornamento narrativa • Apr 19
EVT: Higher Revenue Guidance Will Be Undermined By Weaker Profitability Assumptions
Analysts have adjusted their price target on Evotec to €4.40. The change is framed by updated views on discount rates, revenue growth assumptions, profit margins and a higher future P/E multiple.Aggiornamento narrativa • Apr 05
EVT: 2025 And 2026 Revenue Guidance Will Support Future Upside
Analysts have reduced their price target on Evotec by €1.80, citing updated views on fair value, discount rate, revenue growth and profit margin assumptions, and also reflecting a revised future P/E outlook. What's in the News Evotec issued new earnings guidance for full-year 2026, targeting group revenues of about €700-780 million or €730-810 million at constant exchange rates (Key Developments).Aggiornamento narrativa • Mar 21
EVT: Earnings Outlook Will Balance Higher Guidance With Tighter Profit Assumptions
Analysts have reduced their Evotec price targets from €6.00 to €4.40 as they apply a higher discount rate, assume slower revenue growth and lower profit margins, and factor in a slightly higher future P/E of 24.33x. What's in the News Evotec raised its full-year 2025 earnings guidance, now expecting group revenues of approximately €788 million at the high end of its €760 to €800 million range, or €811 million at constant exchange rates (Key Developments) The company confirmed new earnings guidance for full-year 2026, with group revenues expected in a range of approximately €700 to €780 million, or €730 to €810 million at constant exchange rates (Key Developments) Valuation Changes Fair Value: reduced from €6.00 to €4.40 per share, reflecting a lower implied valuation level.Aggiornamento narrativa • Mar 07
EVT: Future Milestone And Royalty Stream Will Drive Earnings Upside
Analysts have trimmed their price target on Evotec to €10.40. This reflects updated assumptions for revenue growth, profit margins and a higher future P/E multiple.Aggiornamento narrativa • Feb 20
EVT: Kidney Disease Milestone Prospects Will Support Future Upside
Analysts have made only a very small adjustment to their Evotec price target, keeping it effectively unchanged at about €8.72. Updated assumptions for discount rate, revenue growth, profit margin and future P/E remain closely aligned with prior estimates.Aggiornamento narrativa • Feb 06
EVT: Kidney Disease Milestones And Novo Stake Sale Will Support Future Upside
Analysts have adjusted their fair value estimate for Evotec from €8.46 to approximately €8.72, citing updated views on discount rates, revenue growth, profit margins and future P/E assumptions as the main factors behind the latest price target revision. What's in the News Novo Holdings is reportedly planning to sell up to 9.4 million Evotec shares, equal to about 5% of Evotec's share capital, after previously holding 14.9 million shares or 8.4% of the company (Key Developments).Aggiornamento narrativa • Jan 22
EVT: Milestone Progress And Share Buybacks Will Support Future Upside
Analysts have slightly adjusted their price target on Evotec to reflect updated assumptions around discount rate, revenue growth, profit margin and future P/E. The fair value estimate remains steady at €8.46.Aggiornamento narrativa • Jan 07
EVT: Milestone Payment And Buyback Will Support Future Upside
Analysts have kept their fair value estimate for Evotec steady at €8.46, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, reflecting a largely unchanged fundamental view. What's in the News Novo Holdings is reportedly planning to sell up to 9.4 million Evotec shares, around 5% of the company, after previously holding 14.9 million shares or 8.4% of the capital.Aggiornamento narrativa • Dec 17
EVT: Future Milestone And Royalty Stream Will Drive Earnings Upside
Analysts have trimmed their price target on Evotec from €12.00 to €10.40. The revision reflects a higher perceived discount rate despite stronger expectations for revenue growth and profit margins.Aggiornamento narrativa • Dec 03
EVT: Share Buybacks And Milestone Payment Will Support Future Upside
Analysts have lowered their price target on Evotec from approximately $9.47 to about $8.46. They cited a higher perceived discount rate and slightly softer long term revenue growth expectations, partially offset by improved profit margin forecasts and a more moderate future price to earnings multiple.Aggiornamento narrativa • Aug 21
Large Pharma Partnerships And AI Platforms Will Open New Markets
The notable reduction in Evotec’s Analyst Price Target reflects a lower expected future P/E and a slight moderation in revenue growth forecasts, leading to a new consensus fair value of €9.43. What's in the News Evotec lowered FY2025 revenue guidance to EUR 760–800 million (previously EUR 840–880 million) due to changes in revenue mix and higher-than-expected cost savings; technology licensing is expected to contribute more, while Shared R&D faces market challenges.
Nuova narrativa • Apr 30
Pharmaceutical Collaborations And Cost Savings Will Drive Excellence
Strengthened partnerships with major pharma companies and a focus on biologics manufacturing are expected to boost Evotec's revenue and earnings.Articolo di analisi • Nov 10
Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price
Evotec SE ( ETR:EVT ) missed earnings with its latest quarterly results, disappointing overly-optimistic forecasters...Articolo di analisi • Nov 05
A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) 32% Share Price Climb
Those holding Evotec SE ( ETR:EVT ) shares would be relieved that the share price has rebounded 32% in the last thirty...Articolo di analisi • Aug 17
Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price
Investors in Evotec SE ( ETR:EVT ) had a good week, as its shares rose 4.5% to close at €5.80 following the release of...Articolo di analisi • Aug 08
Evotec SE (ETR:EVT) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny
The Evotec SE ( ETR:EVT ) share price has fared very poorly over the last month, falling by a substantial 45%. The...Articolo di analisi • Aug 03
We Think Evotec (ETR:EVT) Has A Fair Chunk Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Rendimenti per gli azionisti
| EVT | DE Life Sciences | DE Mercato | |
|---|---|---|---|
| 7D | -0.5% | 1.9% | 0.3% |
| 1Y | -45.8% | 5.8% | 3.0% |
Ritorno vs Industria: EVT ha avuto una performance inferiore rispetto al German Life Sciences che ha registrato un rendimento 5.8 % nell'ultimo anno.
Rendimento vs Mercato: EVT ha avuto una performance inferiore al mercato German che ha registrato un rendimento 3 % nell'ultimo anno.
Volatilità dei prezzi
| EVT volatility | |
|---|---|
| EVT Average Weekly Movement | 8.7% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 2.7% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di EVT è stato volatile rispetto al mercato German.
Volatilità nel tempo: La volatilità settimanale ( 9% ) di EVT è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni German.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1993 | 4,461 | Christian Wojczewski | www.evotec.com |
Evotec SE opera come partner per la scoperta e lo sviluppo di farmaci per l'industria farmaceutica e biotecnologica a livello mondiale. Opera in due segmenti, Shared R&D e Just Evotec Biologics. L'azienda sta sviluppando prodotti farmaceutici in diverse aree terapeutiche, quali oncologia, autoimmuni, cancro, diabete, insufficienza cardiaca, fibrosi, immunologia, dolore e infiammazione, malattie infettive, renali, epatiche, rare, respiratorie, fibrotiche e metaboliche; disordini del sistema nervoso centrale (SNC) e cardio metabolici; salute degli animali e delle donne.
Evotec SE Riepilogo dei fondamenti
| EVT statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | €630.65m |
| Utili (TTM) | -€197.05m |
| Ricavi(TTM) | €717.28m |
0.9x
Rapporto P/S-3.1x
Rapporto P/EEVT è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| EVT Conto economico (TTM) | |
|---|---|
| Ricavi | €717.28m |
| Costo del fatturato | €656.57m |
| Profitto lordo | €60.71m |
| Altre spese | €257.76m |
| Utili | -€197.05m |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
Nov 05, 2026
| Utile per azione (EPS) | -1.11 |
| Margine lordo | 8.46% |
| Margine di profitto netto | -27.47% |
| Rapporto debito/patrimonio netto | 47.7% |
Come si è comportato EVT nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/14 19:34 |
| Prezzo dell'azione a fine giornata | 2026/08/14 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Evotec SE è coperta da 24 analisti. 10 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Christian Ehmann | Berenberg |
| Michael Ryskin | BofA Global Research |
| Peter Verdult | Citigroup Inc |